Frailty and chronic lymphocytic leukemia: navigating challenges to improve outcomes

Area of Science:

• Hematology
• Geriatrics
• Oncology

Background:

• Targeted therapies have advanced chronic lymphocytic leukemia (CLL) treatment.
• Elderly patients, especially those over 80, are underrepresented in clinical trials.
• Frailty and biological aging present unique challenges in CLL patient selection and care.

Purpose of the Study:

• To review the intersection of frailty and biological aging with CLL.
• To inform risk stratification, treatment decisions, and supportive care for frail CLL patients.
• To address the underrepresentation of elderly patients in clinical trials.

Main Methods:

• Systematic literature search of PubMed and MEDLINE for studies on frail CLL patients.
• Analysis of factors contributing to frailty predisposition in CLL.
• Evaluation of frailty assessment tools and their clinical utility.

Main Results:

• Approximately 20% of CLL patients experience frailty.
• Pre-malignant aging processes like CHIP and MBL contribute to frailty.
• CLL and its treatments exacerbate frailty through cytopenias and organ dysfunction.
• Comprehensive Geriatric Assessment (CGA) is the gold standard but has implementation challenges.
• Pragmatic screening tools (CFS, G8, Fried Phenotype) offer feasible risk stratification.
• Frailty is dynamic, requiring serial monitoring for treatment adjustments.

Conclusions:

• Personalized therapy planning is crucial for optimizing efficacy and minimizing toxicity in elderly/frail CLL patients.
• Future clinical trials should focus on well-characterized older or frail cohorts.
• Trials comparing fixed-duration versus continuous therapy are needed for real-world applicability.